Gordon N F, van Rensburg J P, van den Heever D P, Kalliatakis N B, Myburgh D P
Med Sci Sports Exerc. 1987 Feb;19(1):1-6.
The effect of oral clinically used doses of propranolol, atenolol, nifedipine, propranolol + nifedipine, and atenolol + nifedipine on endurance performance and ventilatory responses to graded treadmill testing was studied in 12 healthy physically active men. Maximal exercise duration was reduced by propranolol (8.5%, P less than 0.001) and its combination with nifedipine (11.1%, P less than 0.001), and to a lesser degree by atenolol (3.2%, 0.05 less than P less than 0.1), nifedipine (2.1%, P less than 0.05), and atenolol + nifedipine (3.9%, P less than 0.01). Exercise duration and heart rate (HR) and ventilatory responses to maximal exercise were equivalent with a beta-blocker and its combination with nifedipine. At submaximal exercise, beta-blockade reduced the HR and oxygen uptake, nifedipine accentuated the HR but did not alter ventilation, and all drugs modified the relative oxygen uptake corresponding to 85% of the maximal HR. Physiologic responses to submaximal exercise during combination therapy were similar to those during beta-blockade alone. This study concludes that, in physically active men, nifedipine induces a small impairment of maximal performance, but does not accentuate the reduction in effort tolerance resulting from beta-blockade. Furthermore, HR and ventilatory responses to exercise during combined beta-blockade and calcium antagonism can be predicted from those during beta-blockade alone.
在12名身体健康、经常运动的男性中，研究了口服临床常用剂量的普萘洛尔、阿替洛尔、硝苯地平、普萘洛尔 + 硝苯地平以及阿替洛尔 + 硝苯地平对耐力表现和分级跑步机测试中通气反应的影响。普萘洛尔（8.5%，P < 0.001）及其与硝苯地平联合使用（11.1%，P < 0.001）可使最大运动持续时间缩短，阿替洛尔（3.2%，0.05 < P < 0.1）、硝苯地平（2.1%，P < 0.05）和阿替洛尔 + 硝苯地平（3.9%，P < 0.01）使最大运动持续时间缩短的程度较小。β受体阻滞剂及其与硝苯地平联合使用时，运动持续时间、心率（HR）和对最大运动的通气反应相当。在次最大运动时，β受体阻滞剂可降低心率和摄氧量，硝苯地平可使心率加快但不改变通气，所有药物均可改变对应于最大心率85%时的相对摄氧量。联合治疗期间对次最大运动的生理反应与单独使用β受体阻滞剂时相似。本研究得出结论，在经常运动的男性中，硝苯地平会对最大运动表现产生轻微损害，但不会加重β受体阻滞剂导致的耐力降低。此外，联合使用β受体阻滞剂和钙拮抗剂时对运动的心率和通气反应可根据单独使用β受体阻滞剂时的反应进行预测。
